{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T15:46:14Z","timestamp":1791906374414,"version":"4.3.4"},"reference-count":7,"publisher":"American Medical Association (AMA)","issue":"14","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2026,10,13]]},"abstract":"<jats:p>The 2026 Lasker-DeBakey Clinical Medical Research Award winners describe the development of a bispecific antibody that mimics blood coagulation factor VIII, revolutionizing the treatment of hemophilia, a life-threatening bleeding disorder caused by lack of factor VIII.<\/jats:p>","DOI":"10.1001\/jama.2026.15612","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T12:30:16Z","timestamp":1788957016000},"page":"1202","source":"Crossref","is-referenced-by-count":0,"title":["From Biological Insight to a New Class of Medicines for Hemophilia A"],"prefix":"10.1001","volume":"336","author":[{"given":"Kunihiro","family":"Hattori","sequence":"first","affiliation":[{"name":"Research Division, Chugai Pharmaceutical Co Ltd, Yokohama, Japan"},{"name":"Japan International Drug Discovery Ecosystem Association, Tokyo, Japan"},{"name":"BiCA Therapeutics Inc, Toyonaka, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehisa","family":"Kitazawa","sequence":"additional","affiliation":[{"name":"Research Division, Chugai Pharmaceutical Co Ltd, Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Igawa","sequence":"additional","affiliation":[{"name":"Research Division, Chugai Pharmaceutical Co Ltd, Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"10","key":"jpp260041r1","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1038\/nm.2942","article-title":"A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model.","volume":"18","author":"Kitazawa","year":"2012","journal-title":"Nat Med"},{"issue":"7","key":"jpp260041r2","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/nbt0798-677","article-title":"An efficient route to human bispecific IgG.","volume":"16","author":"Merchant","year":"1998","journal-title":"Nat Biotechnol"},{"issue":"2","key":"jpp260041r3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0057479","article-title":"Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity.","volume":"8","author":"Sampei","year":"2013","journal-title":"PLoS One"},{"issue":"7","key":"jpp260041r4","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1160\/TH17-01-0030","article-title":"Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX\/IXa and X\/Xa, emicizumab, depends on its ability to bridge the antigens.","volume":"117","author":"Kitazawa","year":"2017","journal-title":"Thromb Haemost"},{"issue":"2","key":"jpp260041r5","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1111\/jth.12474","article-title":"Anti-factor IXa\/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation.","volume":"12","author":"Muto","year":"2014","journal-title":"J Thromb Haemost"},{"issue":"5","key":"jpp260041r6","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.3324\/haematol.2022.282099","article-title":"Emicizumab: the hemophilia A game-changer.","volume":"109","author":"Alcedo Andrade","year":"2024","journal-title":"Haematologica"},{"issue":"3","key":"jpp260041r7","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1080\/17512433.2026.2636123","article-title":"Factor-VIII mimetic bispecific antibodies for the treatment of hemophilia A: an update.","volume":"19","author":"Eduarda Alves de Jesus","year":"2026","journal-title":"Expert Rev Clin Pharmacol"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2853865\/jama_hattori_2026_pp_260041_1790887518.90146.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T15:00:16Z","timestamp":1791903616000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2853865"}},"subtitle":["The 2026 Lasker-DeBakey Clinical Medical Research Award"],"short-title":[],"issued":{"date-parts":[[2026,10,13]]},"references-count":7,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2026,10,13]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2026.15612","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10,13]]}}}